AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00771667 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IV - Nonresponder - Ustekinumab 270/90 mg SC (MP)
Description: Maintenance phase (Week 8-36) (MP) - Receiving Placebo IV at Week 0 - Nonresponder at week 6 - Receiving Ustekinumab 270 mg SC at Week 8 and 90 mg at Week 16
Study NCT00771667 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ustekinumab IV - Responder - Placebo SC (MP)
Description: Maintenance phase (Week 8-36) (MP) - Receiving Ustekinumab IV at Week 0 - Responder at week 6 - Receiving Placebo SC at Week 8 and Week 16
Study NCT00771667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP)
Description: Maintenance phase (Week 8-36) (MP) - Receiving Ustekinumab IV at Week 0 - Responder at week 6 - Receiving Ustekinumab 90 mg SC at Week 8 and Week 16
Study NCT00771667 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ustekinumab IV - Nonresponder - Placebo SC (MP)
Description: Maintenance phase (Week 8-36) (MP) - Receiving Ustekinumab IV at Week 0 - Nonresponder at week 6 - Receiving Placebo SC at Week 8 and Week 16
Study NCT00771667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP)
Description: Maintenance phase (Week 8-36) (MP) - Receiving Ustekinumab IV at Week 0 - Nonresponder at week 6 - Receiving Ustekinumab 90 mg SC at Week 8 and Week 16
Study NCT03391908 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: cardiac imaging tests
Description: Patients will undergo non-invasive Cardiac Computed Tomography for assessment of coronary plaques and myocardial perfusion, and invasive intracoronary imaging tests (coronary angiography, Intravascular ultrasound, optical coherence tomography and FFR). If imaging will reveal existence of a significant coronary plaque, a percutaneous coronary intervention (PCI - stenting) will be performed.
Study NCT02071615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: modafinil 200mg tablet given once by mouth
Description: 3-arm, single-drug dosage comparison study
Study NCT02071615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: caffein 200mg tablet given once by mouth
Description: 3-arm, single-drug dosage comparison study
Study NCT02071615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Study NCT02289625 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Training
Description: six month of Exercise training will be conducted in individuals with moderate to severe sleep apnea. The training include aerobic exercise, resistance exercise, flexibility.
Study NCT04919759 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: R-Enhanced
Description: The R-Enhanced intervention was guided by the Social Cognitive Theory and employed a variety of behavior modification strategies, including self-monitoring, goal setting, self-efficacy, and social support to facilitate changes in diet and physical activity. In addition, participants in the R-Enhanced intervention had online access to a nutritionist. The R-Enhanced intervention was implemented in the United Arab Emirates University.
Study NCT02858726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CR845 0.5 mcg/kg
Description: IV medication delivered three times/week
Study NCT02858726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CR845 1 mcg/kg
Description: IV medication delivered three times/week
Study NCT04371926 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine Sulfate
Description: Patients will receive hydroxychloroquine sulfate 400 mg twice daily on the day of enrollment, then 200 mg twice daily for the next 4 days for a 5 day total course.~Staff will receive HCQ sulfate 400mg/week for 4 weeks
Study NCT03202849 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D and A
Description: A single dose of Vitamin A and Vitamin D will be given.
Study NCT03202849 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D and Placebo
Description: A single dose of Vitamin D plus a placebo will be given.
Study NCT00423007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromfenac
Study NCT00423007 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02488317 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Decision Aid
Description: Decision-making outcomes (e.g., self-efficacy) will be compared between patients who received and did not receive a decision aid. These arms were chosen because the current standard of care is for health care providers to discuss options with patients without using a decision aid.
Study NCT02951117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Tablet
Study NCT02951117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-838
Description: Intravenous infusion
Study NCT01368341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenoxymethylpenicillin
Description: Tablet 650 mg, 2 tablets, t.i.d., 14 days
Study NCT01368341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Capsula, 500 mg, t.i.d., 14 days
Study NCT04451655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continuous insulin infusion
Description: This study aims to explore the hypothesis that diabetic patients undergoing coronary artery bypass graft (CABG) surgery receiving intravenous continuous insulin infusion (CII) for tight glycemic control (110-149 mg/dl) protocol during the intraoperative period would have improved intraoperative glycemic stability, efficacy and consistency compared to patients receiving conventional glycemic control (150-180 mg/dl) protocol during the intraoperative period
Study NCT03174821 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insulin pump
Description: Blood glucose management device
Study NCT00995345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRP-104
Description: Tablet
Study NCT00995345 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet
Study NCT00668759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vernakalant Injection
Description: 10-minute infusion of 3 mg/kg vernakalant injection followed by a 15-minute observation period, followed by an additional 10-minute infusion of 2 mg/kg of vernakalant if required (if the subject is still in AF).
Study NCT02336594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170 10 mg
Study NCT00668759 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone Injection:
Description: 60-minute infusion of 5 mg/kg amiodarone followed by a maintenance infusion of 50 mg amiodarone over an additional 60 minutes (equivalent to approximately 15 mg/kg over 24 hrs).
Study NCT01649193 — intervention group
Intervention type: OTHER
Intervention: Pulmonary rehabilitation
Description: An eight week out-patient based programme consisting of twice weekly supervised exercise and educational sessions
Study NCT00744861 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Exospine sham
Description: Inactive Exospine LIPUS device (dual transducers)
Study NCT00744861 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Exospine
Description: Active Exospine LIPUS device (dual transducers)
Study NCT00744861 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Exogen 4000+
Description: Active Exogen LIPUS device (single transducer)
Study NCT00744861 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Exogen 4000+ sham
Description: Inactive Exogen 4000+ LIPUS device (single transducer)
Study NCT04897568 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient decision aid
Description: Each subject will receive an informational flyer describing lung cancer screening options and smoking cessation from a trained person on the medical staff at each clinic. Staff will lead a shared decision-making discussion with the patient.
Study NCT02858726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CR845 1.5mcg/kg
Description: IV medication delivered three times/week
Study NCT02858726 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV medication delivered three times/week
Study NCT02304068 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Home monitoring
Study NCT02304068 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Hospital assessment
Study NCT04329416 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Predicted depth of insertion
Description: A left-sided double-lumen tube was introduced beyond the vocal cords when the train-of-four stimulation of the ulnar nerve revealed 1 or 2 twitches, the stylet was removed, the double-lumen tube was rotated 90° counterclockwise and then advanced blindly to the predicted depth of insertion.
Study NCT04329416 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Optimized depth of insertion
Description: The optimal position of the double-lumen tube, defined as the inflated endobronchial cuff is placed in the left main bronchus just below the carina without herniation, which was confirmed using a flexible bronchoscope in both supine and lateral decubitus positions.
Study NCT04329416 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Adjustment of depth of insertion
Description: If the endobronchial cuff was placed too deeply or too proximal, subsequently, the double-lumen tube was withdrawn or advanced, respectively, using the flexible bronchoscope until the optimum position of the double-lumen tube was achieved.
Study NCT01158326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Resfenol
Description: Paracetamol (acetaminophen), chlorpheniramine maleate, phenylephrine hydrochloride.~10 ml of oral solution acetaminophen, chlorpheniramine maleate, phenylephrine hydrochloride every 6 hours for 48 hours.
Study NCT01158326 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 ml of oral placebo every 6 hours for 48 hours
Study NCT00537199 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Visual Examination
Description: Two (2) scheduled visits for visual examination of mouth for abnormal lesions and glands in the neck.
Study NCT00537199 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: OraTest
Description: Two (2) scheduled visits for rinse staining: 2 teaspoons of OraTest for 20 seconds, then spit.
Study NCT00272649 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGS-003
Description: Dendritic cell, autologous cellular immunotherapy. (Arcelis platform)
Study NCT03856905 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy program
Description: It will consist of gentle stretching exercises for spastic muscles, facilitation of muscle contraction for the anti-spastic muscles, proprioceptive training, balance and postural control exercises, neurodevelopmental techniques, and gait training.
Study NCT03856905 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy program
Description: It will consist of gentle stretching exercises for spastic muscles, facilitation of muscle contraction for the anti-spastic muscles, proprioceptive training, balance and postural control exercises, neurodevelopmental techniques, and gait training.
Study NCT03856905 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy
Description: It is an electromagnetic coil lithotripter (Modulith SLK; Storz Medical AG, Tagerwillen, Switzerland) provided with in-line ultrasound, radiographic, and computerized aiming (Lithotrack system; Storz Medical AG). The energy applied will be 0.030 mJ/mm2. The frequency will be 5 Hz, with a pressure of 1.5 bars, burst mode.
Study NCT03856905 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation
Description: It is a highly advanced medical device that consists of a battery-operated, single-channel electrical stimulator, two electrodes, and electrode leads with a cuff holds the system in place. The stimulation parameters will include pulse frequency (16-33 pulses per second), pulse width (25-300 µs) to produce a desired movement as close to normal as possible at the ankle during gait.
Study NCT00576303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta [Mircera]
Description: 120, 200 or 360 micrograms iv monthly (starting dose)
Study NCT02951117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Tablet or intravenous infusion
Study NCT01680276 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PBS based staff training
Description: Please see published study protocol for more information:~http://www.biomedcentral.com/1471-244X/14/219
Study NCT01680276 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: http://www.biomedcentral.com/1471-244X/14/219
Study NCT01680276 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as Usual
Description: http://www.biomedcentral.com/1471-244X/14/219
Study NCT00757718 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: One half of the subjects will be randomly assigned to wear continuous a positive airway pressure device on the second night of the study. Portable polysomnography will be repeated for this night and morning bloodwork for inflammatory markers will be repeated.
Study NCT00757718 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oral Appliance
Description: Half of the subjects will be assigned to wear an oral appliance and nasal strip on the second night of the study. Repeat portable polysomnography will be performed and morning bloodwork will again be drawn for inflammatory markers.
Study NCT01817036 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo
Study NCT01817036 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT01817036 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 400 IU vitamin D per pill
Study NCT03182036 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Portable pulsed oxygen
Description: Hypoxemic patients will use portable pulsed oxygen at rest, and while performing a six-minute walk test.
Study NCT05001919 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: GTR
Description: intrabony defects treated by surgery and bone graft +collagen membrane
Study NCT05001919 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: concentrated growth factor
Description: intrabony defects treated by surgery and bone graft +concenrated growth factor membrane
Study NCT04436055 — intervention group
Intervention type: OTHER
Intervention: No Intervention will be used
Description: Since this is an observational study, there are no interventions.
Study NCT00315120 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: A. Active OMT and active UST
Description: Active osteopathic manipulation (OMT) and active ultrasound physical therapy (UST)
Study NCT00315120 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: B. Sham OMT and active UST
Description: Sham osteopathic manipulation (OMT) and active ultrasound physical therapy (UST)
Study NCT00315120 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: C. Active OMT and sham UST
Description: Active osteopathic manipulation (OMT) and sham ultrasound physical therapy (UST)
Study NCT00315120 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: D. Sham OMT and sham UST
Description: Sham osteopathic manipulation (OMT) and sham ultrasound physical therapy (UST)
Study NCT04423484 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Clinical stage, treatment given and observations of toxicity if any, outcome following treatment and follow up.
Study NCT02161653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone plus Metadoxine
Study NCT02161653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline plus Metadoxine
Study NCT01048788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-41061
Description: OPC-41061 tablets will be orally administered once daily after breakfast at 7.5 mg on Day 1 to 7 and at either 7.5 or 15 mg on Day 8 to 14.
Study NCT00562913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexavar (Sorafenib, BAY43-9006)
Description: Cyclophosphamide plus 400 mg BID sorafenib and doxorubicin
Study NCT04009226 — intervention group
Intervention type: OTHER
Intervention: Patient Registry
Description: Participants who have volunteered to participate will complete various questionnaires relating to their condition.
Study NCT01189006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Description: Add-On double-blind study treatment commenced at randomization for 11 weeks while patients were continuing open-label risperidone. Randomization was immediately preceded by a one week open-label Risperidone-Only Treatment period. Patients who were receiving antipsychotics medication(s) at screen other than risperidone alone was withdrawn from previous non-risperidone medication(s) and at the same time commenced risperidone in titrating doses over a week. This Antipsychotic Switch-Over Period occurred between Screen and Risperidone-Only Treatment period. Patients remained hospitalized for at least during the Risperidone-Only treatment Period and first week of Add-On treatment Period.
Study NCT02533908 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl intranasal
Description: fentanyl is applied intranasally with a MAD (mucosal atomization device) prior to the application of nitrous oxide 70% analgosedation
Study NCT02533908 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0.9% intranasal
Description: Placebo is applied intranasally with a MAD (mucosal atomization device) Prior to the application of nitrous oxide 70% analgosedation
Study NCT02465086 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training of linguistic recursion
Description: Training of recursion comprehension will include cooperative dialogue and feedback on the sentences and small dialogues. The training conditions will be further divided into marking the change of the truth-value.
Study NCT03203018 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive workshop based on community specific needs
Description: Intervention components will include lecture on women's CVD, workshop on how to prepare for a doctor's visit, patient's rights and patient-doctor communication skills, and a know your numbers workshop, including understanding blood test results.
Study NCT04538248 — intervention group
Intervention type: OTHER
Intervention: Combined rehabilitation during hemodialysis
Description: Combined rehabilitation during hemodialysis
Study NCT03482219 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Occupational therapy
Description: The Occupational therapy intervention includes various thermal modalities, manual therapy, Physiotouch (Healthy Life Devices Ltd) and education. The home app intervention involves one session of education with the occupational therapist.
Study NCT03482219 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home app intervention
Description: The app consists of videos depicting each exercise and ability to track adherence to exercises.
Study NCT02423993 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Knowledge assessment
Description: For the knowledge assessment of disease management the standard Questionnaire for patients with type 1 diabetes will be used. Maximum score equals 37 grades; the satisfactory level of knowledge is scored 27.
Study NCT02423993 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Knowledge assessment
Description: For the knowledge assessment of disease management the standard Questionnaire for patients with type 1 diabetes will be used. Maximum score equals 37 grades; the satisfactory level of knowledge is scored 27.
Study NCT02552992 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Study NCT02552992 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Directed Mind-Body Program
Study NCT04487106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV or SC
Study NCT04487106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO
Study NCT04487106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study NCT02683720 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ONS
Description: randomized clinical trial involving different ONS strategies
Study NCT02683720 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ONS
Description: randomized clinical trial involving different ONS strategies